Analytical Data
-
Gene name
CYSLTR1
- Application
-
Alternative Names
CysLTR1;Cysteinyl leukotriene D4 receptor;LTD4 receptor;G-protein coupled receptor HG55;HMTMF81
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y271
-
Expression Region
1-337aa
-
Molecular Weight
44.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYSLTR1, or Cysteinyl Leukotriene Receptor 1, is a G protein-coupled receptor (GPCR) that plays a significant role in various physiological processes, particularly in respiratory and inflammatory responses. It is primarily activated by cysteinyl leukotrienes, which are lipid mediators produced during immune responses and have been implicated in conditions such as asthma, allergic rhinitis, and other inflammatory diseases. Given the receptor's involvement in these pathologies, research has focused on its structure, function, and potential as a therapeutic target. The study of CYSLTR1 recombinant proteins has gained traction, enabling scientists to investigate its signaling mechanisms and the effects of various ligands at the molecular level. Understanding CYSLTR1's interactions and conformational dynamics is crucial for the development of specific antagonists that can inhibit its activity, thereby offering new treatments for conditions characterized by excessive inflammation or bronchoconstriction. Recent advancements in protein engineering and structure-based drug design have provided tools to analyze CYSLTR1 in detail, facilitating insights into its role in disease and paving the way for innovative therapeutic strategies. As research progresses, the recombinant expression and purification of CYSLTR1 not only enhance our understanding of this receptor but also open new avenues for pharmacological intervention in related diseases.
